Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech buyouts.

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Oct 10, 2022 1:39pm

143 Views

Post# 35015867

RE:RE:RE:RE:RE:RE:RE:RE:Biotech buyouts.

Thank you for explaining page 38. It is strange that AN appears not to be going forward with pela. Their own words were not particularly encouraging. If they do not go forward I wonder what happens to the deal with ONC. Can AN sell the rights or do they revert back to ONC.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023